Literature DB >> 16440226

Safety of the long-time monthly triple dose of a Gd-based contrast agent.

Francesco Sardanelli, Gianluigi Mancardi, Massimo Filippi.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 16440226     DOI： 10.1007/s00330-003-1830-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN： 0938-7994            Impact factor:   5.315


× No keyword cloud information.
  11 in total

1.  Safety and effectiveness of single- versus triple-dose gadodiamide injection- enhanced MR angiography of the abdomen: a phase III double-blind multicenter study.

Authors:  S A Thurnher; A Capelastegui; F H Del Olmo; R F Dondelinger; C Gervás; A G Jassoy; P Keto; C Loewe; C N Ludman; L Marti-Bonmati; M Meusel; J P da Cruz; J P Pruvo; V M Sanjuan; T Vogl
Journal:  Radiology       Date:  2001-04       Impact factor: 11.105

2.  Gadolinium-DTPA as X-ray contrast medium in clinical studies.

Authors:  T Albrecht; P Dawson
Journal:  Br J Radiol       Date:  2000-08       Impact factor: 3.039

3.  Gd-enhanced MR imaging of brain metastases: contrast as a function of dose and lesion size.

Authors:  P Van Dijk; P E Sijens; P I Schmitz; M Oudkerk
Journal:  Magn Reson Imaging       Date:  1997       Impact factor: 2.546

4.  Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS.

Authors:  G L Mancardi; R Saccardi; M Filippi; F Gualandi; A Murialdo; M Inglese; M G Marrosu; G Meucci; L Massacesi; A Lugaresi; F Pagliai; M P Sormani; F Sardanelli; A Marmont
Journal:  Neurology       Date:  2001-07-10       Impact factor: 9.910

5.  A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials.

Authors:  M Filippi; M Rovaris; R Capra; C Gasperini; T A Yousry; M P Sormani; F Prandini; M A Horsfield; V Martinelli; S Bastianello; I Kühne; C Pozzilli; G Comi
Journal:  Brain       Date:  1998-10       Impact factor: 13.501

6.  Triple dose of gadolinium-DTPA increases the sensitivity of spinal cord MRI in detecting enhancing lesions in multiple sclerosis.

Authors:  T A Yousry; G Fesl; E Walther; R Voltz; M Filippi
Journal:  J Neurol Sci       Date:  1998-06-30       Impact factor: 3.181

7.  Comparison of the safety of standard and triple dose gadodiamide injection in MR imaging of the central nervous system. A double-blind study.

Authors:  M G Svaland; T Christensen; E Lundorf
Journal:  Acta Radiol       Date:  1994-07       Impact factor: 1.990

8.  Gadolinium-containing contrast media for radiographic examinations: a position paper.

Authors:  Henrik S Thomsen; Torsten Almèn; Sameh K Morcos
Journal:  Eur Radiol       Date:  2002-08-16       Impact factor: 5.315

9.  MRI evaluation of "solitary" brain metastases with triple-dose gadoteridol: comparison with contrast-enhanced CT and conventional-dose gadopentetate dimeglumine MRI studies in the same patients.

Authors:  M J Kuhn; G M Hammer; L C Swenson; H T Youssef; T J Gleason
Journal:  Comput Med Imaging Graph       Date:  1994 Sep-Oct       Impact factor: 4.790

10.  Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS.

Authors:  M Filippi; T Yousry; A Campi; C Kandziora; B Colombo; R Voltz; V Martinelli; S Spuler; S Bressi; G Scotti; G Comi
Journal:  Neurology       Date:  1996-02       Impact factor: 9.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.